[Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer].

Abstract

BACKGROUND:

Programmed cell death 1 or programmed cell death ligand 1 inhibitor (PD-1/PD-L1 inhibitor) and docetaxel, as the standard second-line treatments of advanced non-small cell lung cancer (NSCLC) patients, have limited effects. There are few studies on whether docetaxel combined with PD-1/PD-L1 inhibitor can increase the efficacy and make patients better benefit. The aim of this study is to evaluate the efficacy and safety of docetaxel combined with PD-1/PD-L1 inhibitor for the second-line treatment of stage IV NSCLC patients.

METHODS:

Stage IV NSCLC patients (n=118) who received treatment at Shandong Cancer Hospital between October 1, 2018, and December 31, 2020, were retrospectively analyzed. They were divided into observation group (n=69) and control group (n=49) according to different treatment plan. Observation group was given docetaxel plus PD-1/PD-L1 inhibitor, while control group was given PD-1/PD-L1 inhibitor. The clinical curative effect and the incidence of adverse reactions of grade 3 and above were compared between the two groups.

RESULTS:

The disease control rate (DCR) was higher in the observation group (89.9%) than that in the control group (73.5%) (P=0.019), and the objective response rate (ORR) showed no significant difference between observation group (24.6%) and control group (16.3%) (P=0.276). Till June 22, 2021, the 1-year PFS rate showed no difference between observation group (16.5%) and control group (7.7%) (P=0.205). During the treatment period, the adverse reactions of the two groups were mostly grade 1 to 2, and could be tolerated. The incidence of bone marrow suppression in observation group was higher than that in the control group (P<0.05), and the remaining adverse reactions were not statistically different from control group. Cox regression analysis showed that performance status (PS) (P=0.020) and age (P=0.049) were independent prognostic factors for the effect of docetaxel combined with PD-1/PD-L1 inhibitor.

CONCLUSIONS:

The second-line treatment with docetaxel plus PD-1/PD-L1 inhibitor in patients with stage IV NSCLC can improve the DCR and prolong the PFS, and the adverse reactions are tolerable.

• Authors: Qing Chen, Yan Li, Wenjie Zhang, Shengjie Yang, Chen Wang, Qisen Guo, Wenna Shi
• Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer (Zhongguo Fei Ai Za Zhi) Vol. 24 Issue 9 Pg. 605-612 (Sep 20 2021) ISSN: 1999-6187 [Electronic] China
• PMID: 34455735 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• B7-H1 Antigen
• CD274 protein, human
• Immune Checkpoint Inhibitors
• PDCD1 protein, human
• Programmed Cell Death 1 Receptor
• Docetaxel

Topics

• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• B7-H1 Antigen (antagonists & inhibitors)
• Carcinoma, Non-Small-Cell Lung (drug therapy, mortality, pathology)
• Docetaxel (adverse effects, therapeutic use)
• Female
• Humans
• Immune Checkpoint Inhibitors (adverse effects, therapeutic use)
• Lung Neoplasms (drug therapy, mortality, pathology)
• Male
• Middle Aged
• Programmed Cell Death 1 Receptor (antagonists & inhibitors)
• Retrospective Studies